Patent estate

NESHER PHARMS — Patent Portfolio

1 drug with active patents · 2 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 2/2 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

Patent estate by drug

Micro-K 10 (POTASSIUM CHLORIDE)

Cliff 2039 · 13y
Formulation 2
  • US12539314 Vuln 55 2039-03-07
    This patent protects an oral liquid composition of potassium chloride that is free of alcohol and parabens and has enhanced stability.
  • US12539314 Vuln 55 2039-03-07
    This patent protects an oral liquid composition of potassium chloride that is free of alcohol and parabens and has enhanced stability.

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Formulation 2 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track NESHER PHARMS's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export